Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis

CONCLUSIONS: PARPi was observed with a significantly improved efficacy in aspects of PFS and ORR, but also higher risk of grade 3-4 thrombocytopenia as compared to chemotherapy. PARPi was a better choice for patients who had not received previous platinum treatment.PMID:34130011 | DOI:10.1016/j.breast.2021.05.009

Source: Breast - June 15, 2021 Category: Cancer & Oncology Authors: Xiao-Fei Chang Xiao-Lu Ren Jie-Quan Yang Jian-Jun Shi Jun-Heng Bai Meng-Sheng Cui Wen-Wen Dong Source Type: research